PMID- 24965407
OWN - NLM
STAT- MEDLINE
DCOM- 20140918
LR  - 20190221
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 19
IP  - 2
DP  - 2014 Apr-Jun
TI  - Gefitinib as first-line treatment for patients with epidermal growth factor 
      receptor-mutated advanced lung adenocarcinoma: a single institution experience in 
      Taiwan.
PG  - 459-65
AB  - PURPOSE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 
      (TKIs) represent a new treatment option for patients with advanced lung 
      adenocarcinoma. In this article we assessed the treatment response and tried to 
      identify prognostic factors which may provide some information different from 
      previously published reports in groups with better performance status (PS) than 
      our enrolled patients. METHODS: The records of 85 patients with EGFR-mutated 
      advanced lung adenocarcinoma who received gefitinib 250 mg once daily as 
      front-line monotherapy between October 2007 and October 2012 were analysed. 
      Direct sequencing methods were used for detecting EGFR mutations. SPSS (version 
      20) software was used for all data analysis. RESULTS: The median overall survival 
      (OS) and progression free survival (PFS) were 25.6 and 6.9 months, respectively. 
      No statistical significance between the two groups of exon 19 and exon 21 in OS 
      and PFS was registered (p=0.414 and p=0.519, respectively). The group of patients 
      treated > 3 months had a better median OS survival compared with those treated < 
      3 months (25.6 vs 4.9 months, p<0.001). In multivariate analysis, significant 
      benefit on OS was observed in patients with ECOG PS scores of 0-2 (p=0.002) and 
      those treated for longer time periods (p<0.001), rather than age, sex and 
      smoking. Among the adverse effects (AEs), skin manifestation was correlated with 
      significantly better OS (p=0.007) but insignificant effect on PFS (p=0.131). 
      CONCLUSIONS: Good ECOG PS, longer TKI use and skin rash were significant factors 
      predictive for gefitinib antitumor activity.
FAU - Lai, Shiue-Wei
AU  - Lai SW
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Tri-Service 
      General Hospital, National Defense Medical Center, Taipei, Taiwan.
FAU - Ho, Ching-Liang
AU  - Ho CL
FAU - Dai, Ming-Shen
AU  - Dai MS
FAU - Chen, Wei-Liang
AU  - Chen WL
FAU - Chang, Ping-Ying
AU  - Chang PY
FAU - Wu, Yi-Ying
AU  - Wu YY
FAU - Perng, Cherng-Lih
AU  - Perng CL
FAU - Lai, Chung-Yu
AU  - Lai CY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/genetics/mortality
MH  - Adenocarcinoma of Lung
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - ErbB Receptors/*antagonists & inhibitors/genetics
MH  - Female
MH  - Gefitinib
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics/mortality
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Quinazolines/adverse effects/*therapeutic use
EDAT- 2014/06/27 06:00
MHDA- 2014/09/19 06:00
CRDT- 2014/06/27 06:00
PHST- 2014/06/27 06:00 [entrez]
PHST- 2014/06/27 06:00 [pubmed]
PHST- 2014/09/19 06:00 [medline]
PST - ppublish
SO  - J BUON. 2014 Apr-Jun;19(2):459-65.